Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03181932 · ClinicalTrials.gov registry record · Phase 3
AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis
A Phase 3 study, sponsored by Savara.
- Completed
- Registry status
- Phase 3
- Development phase
- 188
- Enrollment target
NCT03181932 is a Phase 3 study that has completed, run by Savara. The registered enrollment target is 188 participants.
The verdict
NCT03181932, a Phase 3 study, has completed, sponsored by Savara.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 188 participants
- Enrollment target
Study Summary
This is a multi-center, randomized phase III study to evaluate the clinical effectiveness of AeroVanc in persistent methicillin-resistant Staphylococcus aureus (MRSA) infection in patients with cystic fibrosis (CF).
Interventions
- DRUG Placebo inhalation powder
- DRUG Vancomycin inhalation powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2017-09-20 |
| Est. Completion | 2021-01-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03181932
The ClinicalTrials.gov registry entry for NCT03181932 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 188 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Savara, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo inhalation powder is the first listed.
NCT03181932 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03181932 about?
NCT03181932 is a clinical study titled "AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis". This is a multi-center, randomized phase III study to evaluate the clinical effectiveness of AeroVanc in persistent methicillin-resistant Staphylococcus aureus (MRSA) infection in patients with cystic fibrosis (CF).
What is the current status of trial NCT03181932?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 188 participants. The study started on 2017-09-20. Estimated completion is 2021-01-15.
What interventions are being tested in trial NCT03181932?
The interventions under investigation include: Placebo inhalation powder (DRUG), Vancomycin inhalation powder (DRUG).
Who is sponsoring clinical trial NCT03181932?
This trial is sponsored by Savara, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.